Evidence map›Paper›PMID 27827859›Full record

ArticleJournal of personalized medicine2016

Precision Health Economics and Outcomes Research to Support Precision Medicine: Big Data Meets Patient Heterogeneity on the Road to Value.

Yixi Chen, Gregory F Guzauskas, Chengming Gu, Bruce C M Wang, Wesley E Furnback, Guotong Xie, Peng Dong, Louis P Garrison

Abstract read
In one paragraph

Article in Journal of personalized medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Common Items on a Bucket List.Journal of palliative medicine · 2018
    Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Yixi ChenMedical, Pfizer Investment Co. Ltd., Beijing 100010, China. YiXi.Chen@pfizer.com.
Gregory F GuzauskasDepartment of Pharmacy, University of Washington, Seattle, WA 98195, USA. greguz@uw.edu.
Chengming GuMedical, Pfizer Investment Co. Ltd., Beijing 100010, China. ChengMing.Gu@pfizer.com.
Bruce C M WangDepartment of Pharmacy, University of Washington, Seattle, WA 98195, USA. bruce.wang@elysiagroup.com.
Wesley E FurnbackElysia Group, LLC, New York, NY 10016, USA. Wes.furnback@elysiagroup.com.
Guotong XieIBM Research, Beijing 100010, China. XIEGUOT@cn.ibm.com.
Peng DongMedical, Pfizer Investment Co. Ltd., Beijing 100010, China. Peng.Dong@pfizer.com.
Louis P GarrisonDepartment of Pharmacy, University of Washington, Seattle, WA 98195, USA. lgarrisn@uw.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The "big data" era represents an exciting opportunity to utilize powerful new sources of information to reduce clinical and health economic uncertainty on an individual patient level. In turn, health economic outcomes research (HEOR) practices will need to evolve to accommodate individual patient-level HEOR analyses. We propose the concept of "precision HEOR", which utilizes a combination of costs and outcomes derived from big data to inform healthcare decision-making that is tailored to highly specific patient clusters or individuals. To explore this concept, we discuss the current and future roles of HEOR in health sector decision-making, big data and predictive analytics, and several key HEOR contexts in which big data and predictive analytics might transform traditional HEOR into precision HEOR. The guidance document addresses issues related to the transition from traditional to precision HEOR practices, the evaluation of patient similarity analysis and its appropriateness for precision HEOR analysis, and future challenges to precision HEOR adoption. Precision HEOR should make precision medicine more realizable by aiding and adapting healthcare resource allocation. The combined hopes for precision medicine and precision HEOR are that individual patients receive the best possible medical care while overall healthcare costs remain manageable or become more cost-efficient.

Indexed as

big dataprecision health economicsprecision medicine

Identifiers

PMID27827859
PMCPMC5198059

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.